Pharmaceutical policy -- United States
Resource Information
The concept Pharmaceutical policy -- United States represents the subject, aboutness, idea or notion of resources found in Biddle Law Library - University of Pennsylvania Law School.
The Resource
Pharmaceutical policy -- United States
Resource Information
The concept Pharmaceutical policy -- United States represents the subject, aboutness, idea or notion of resources found in Biddle Law Library - University of Pennsylvania Law School.
- Label
- Pharmaceutical policy -- United States
73 Items that share the Concept Pharmaceutical policy -- United States
Context
Context of Pharmaceutical policy -- United StatesSubject of
No resources found
No enriched resources found
- Acceptable risks
- Advisory Committee on the Food and Drug Administration : final report : hearing of the Committee on Labor and Human Resources, United States Senate, One Hundred Second Congress, first session, on reviewing the Advisory Committee on the Food and Drug Administration report on the current state of FDA, and its recommendations to strengthen FDA, May 15, 1991
- Amendments to Food and Drug Act : hearings before the United States Senate Committee on Interstate and Foreign Commerce, Subcommittee on S. 1190 and H.R. 4071, Eightieth Congress, second session, on Apr. 17, 1948
- CMS pharmaceutical manufacturer enforcement actions
- Council on Competitiveness and FDA plans to alter the drug approval process at FDA : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, second session, March 19, 1992
- DOD pharmacy program : continued efforts needed to reduce growth in spending at retail pharmacies : report to congressional committees
- Department of Veterans Affairs pharmaceutical procurement policy : hearing before the Subcommittee on Health of the Committee on Veterans' Affairs, House of Representatives, One Hundred Sixth Congress, second session, July 25, 2000
- Department of Veterans Affairs pharmacy program with emphasis on OTC drugs, medical supplies, and dietary supplements : hearing before the Subcommittee on Hospitals and Health Care of the Committee on Veterans' Affairs, House of Representatives, One Hundred Fourth Congress, second session, June 11, 1996
- Direct-to-consumer advertising of prescription drugs
- Drug Industry Antitrust Act : hearings before the United States House Committee on the Judiciary, Subcommittee on Antitrust, Eighty-Seventh Congress, second session, on May 17, 18, 23, 24, 1962
- Drug importation : from "quick fix" to "quagmire" via public policy, economics and the law
- Drug importation : the realities of safety and security : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, first session, on examining the realities of safety and security regarding drug importation, February 16, 2005
- Drug importation : would the price be right? : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, first session, on examining the price of drug reimportation, focusing on implications for United States consumers, pricing, research and development, and innovation, February 17, 2005
- Drug lag : hearing before the Subcommittee on Natural Resources, Agriculture Research, and Environment of the Committee on Science and Technology, U.S. House of Representatives, Ninety-seventh Congress, first session, September 16, 1981
- Drug regulation reform--oversight : hearing before the Subcommittee on Health and the Environment of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-sixth Congress, second session
- Drug safety : an update from the Food and Drug Administration : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eleventh Congress, second session, March 10, 2010
- Drug shortages : FDA's ability to respond should be strengthened : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate
- Drug wars : how big pharma raises prices and keeps generics off the market
- Drug wars : how big pharma raises prices and keeps generics off the market
- Drugs and society
- Evaluating the effectiveness of the Food And Drug Administration Modernization Act : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, first session, May 3, 2001
- Evaluating the effectiveness of the Food and Drug Administration Modernization Act : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, first session, May 3, 2001
- Examining drug shortages and recent efforts to address them : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, February 10, 2014
- Examining prescription drug importation : a review of a proposal to allow third parties to reimport prescription drugs : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, July 25, 2002
- Examining the Senate and House versions of the "Greater Access to Affordable Pharmaceuticals Act" : hearing before the Committee on the Judiciary, United States Senate, One Hundred Eighth Congress, first session, August 1, 2003
- Examining the impact of voluntary restricted distribution systems in the pharmaceutical supply chain : hearing before the Subcommittee on Healthcare, Benefits, and Administrative Rules of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fifteenth Congress, first session, March 22, 2017
- Examining the implications of drug importation : hearing before the Committee on the Judiciary, United States Senate, One Hundred Eighth Congress, second session, July 14, 2004
- Examining the implications of drug importation : hearing before the Committee on the Judiciary, United States Senate, One Hundred Eighth Congress, second session, July 14, 2004
- FDA resources
- FDA's drug approval process : up to the challenge? : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, first session, on examining Food and Drug Administration's (FDA) drug approval process, focusing on FDA's drug approval process after a sponsor demonstrates that their benefits outweigh their risks for a specific population and use, and that the drug meet [sic] meets standards for safety and efficacy, March 1, 2005
- FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session
- Federal and private roles in the development and provision of alglucerase therapy for Gaucher disease
- Final report
- Granting additional market exclusivity to the drug Ansaid : hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, second session, February 20, 1992
- Importation of prescription drugs : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Eighth Congress, second session, on examining prescription drug reimportation, focusing on efforts to reduce drug costs, patient safety concerns, recent state action, fraudulent and counterfeit drugs, an international comparison of rising prescription drug expenditures, and S. 2328, to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs, May 20, 2004
- Interagency Coordination in Drug Research and Regulation : hearings before the United States Senate Committee on Government Operations, Subcommittee on Reorganization and International Organizations, Eighty-Eighth Congress, first session, on June 26, 1963, Part 6
- Lower Drug Costs Now Act of 2019 : report of the Committee on Energy and Commerce
- Medicaid waivers : HHS approvals of pharmacy plus demonstrations continue to raise cost and oversight concerns : report to the Committee on Finance, U.S. Senate
- Messing with success : how CMS' attack on the Part D program will increase costs and reduce choices for seniors : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, February 26, 2014
- Nonprescription drugs : considerations regarding a behind-the-counter drug class : report to congressional requesters
- Our right to drugs : the case for a free market
- Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 : report together with additional views (to accompany H.R. 5333) (including cost estimate of the Congressional Budget Office)
- Oversight hearing on the availability and eligibility for pharmaceutical services provided by the Department of Veterans Affairs : hearing before the Subcommittee on Health of the Committee on Veterans' Affairs, House of Representatives, One Hundred Eight [sic] Congress, first session, March 19, 2003
- Oxycontin and beyond : examining the role of FDA and DEA in regulating prescription painkillers : hearing before the Subcommittee on Regulatory Affairs of the Committee on Government Reform, House of Representatives, One Hundred Ninth Congress, first session, September 13, 2005
- Pharmaceutical innovation--promises and problems : hearing before the Subcommittee on Natural Resources, Agriculture Research, and Environment and the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives, Ninety-seventh Congress, first session, April 27, 1981
- Pharmacopolitics : drug regulation in the United States and Germany
- Pill mills, Medicaid fraud, and the diversion of pharmaceuticals : hearing before the Select Committee on Narcotics Abuse and Control, House of Representatives, One Hundred Second Congress, second session, July 29, 1992
- Policy implications of pharmaceutical importation for U.S. consumers : hearing before the Subcommittee on Interstate Commerce, Trade, and Tourism of the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Tenth Congress, first session, March 7, 2007
- Preliminary report of the survey on drugs for rare disease
- Prescription drug abuse : what is being done to address this new drug epidemic? : hearing before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the Committee on Government Reform, House of Representatives, One Hundred Ninth Congress, second session, July 26, 2006
- Prescription drug abuse : what is being done to address this new drug epidemic? : hearing before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the Committee on Government Reform, House of Representatives, One Hundred Ninth Congress, second session, July 26, 2006
- Prescription drug price inflation : are prices rising too fast? : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eleventh Congress, first session, December 8, 2009
- Prescription drug prices : should the federal government regulate them?
- Prescription drug shortages : examining a public health concern and potential solutions : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Twelfth Congress, first session ... December 15, 2011
- Prescription drugs : FDA's oversight of the promotion of drugs for off-label uses : report to the Ranking Member, Committee on Finance, U.S. Senate
- Prescription drugs : strategic framework would promote accountability and enhance efforts to enforce the prohibitions on personal importation : report to Congressional requesters
- Prescription drugs : strategic framework would promote accountability and enhance efforts to enforce the prohibitions on personal importation : report to congressional requesters
- RU-486, status report on the U.S. commercialization project, transfer of antiprogestin technology to the United States : hearing before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, second session, Washington, DC, May 16, 1994
- Recent developments which may impact consumer access to, and demand for, pharmaceuticals : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, first session, June 13, 2001
- Reputation and power : organizational image and pharmaceutical regulation at the FDA
- Seniors' access to affordable prescription drugs : models for reform : hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives, One Hundred Sixth Congress, second session, February 16, 2000
- The Food and Drug Administration's process for approving new drugs : oversight : hearings before the Subcommittee on Science, Research, and Technology of the Committee on Science and Technology, U.S. House of Representatives, Ninety-sixth Congress, first session, June 19, 21, July 11, 1979
- The Food and Drug Administration's process for approving new drugs : report
- The Heperin disaster : Chinese counterfeits and American failures : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, April 29, 2008
- The Quayle Council's plans for changing FDA's drug approval process : a prescription for harm : twenty-sixth report
- The adequacy of FDA to assure the safety of the nation's drug supply : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, February 13, March 22, 2007
- The cost of prescription drugs : examining the President's blueprint 'American Patients First' to lower drug prices : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fifteenth Congress, second session, on examining the cost of prescription drugs, focusing on examining the President's blueprint Àmerican Patients First' to lower drug prices, June 12, 2018
- The effect of federal ban of RU 486 on medical research, new drug development, and pharmaceutical manufacturers : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred Second Congress, second session, Washington, DC, July 28, 1992
- The federal government's investment in new drug research and development : are we getting our money's worth? : hearing before the Special Committee on Aging, United States Senate, One Hundred Third Congress, first session, Washington, DC, February 24, 1993
- The risks of prescription drugs
- The war on drugs meets the war on pain : nursing home patients caught in the crossfire : listening session before the Special Committee on Aging, United States Senate, One Hundred Eleventh Congress, second session, Washington, DC, March 24, 2010
- Uncertain returns : the multimillion dollar market in reimported pharmaceuticals : a staff report
- What is the U.S. role in combating the global HIV/AIDS epidemic? : hearing before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the Committee on Government Reform, House of Representatives, One Hundred Sixth Congress, first session, July 22, 1999
Embed
Settings
Select options that apply then copy and paste the RDF/HTML data fragment to include in your application
Embed this data in a secure (HTTPS) page:
Layout options:
Include data citation:
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.law.upenn.edu/resource/t8fZz9Y_pGw/" typeof="CategoryCode http://bibfra.me/vocab/lite/Concept"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.law.upenn.edu/resource/t8fZz9Y_pGw/">Pharmaceutical policy -- United States</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.law.upenn.edu/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.law.upenn.edu/">Biddle Law Library - University of Pennsylvania Law School</a></span></span></span></span></div>
Note: Adjust the width and height settings defined in the RDF/HTML code fragment to best match your requirements
Preview
Cite Data - Experimental
Data Citation of the Concept Pharmaceutical policy -- United States
Copy and paste the following RDF/HTML data fragment to cite this resource
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.law.upenn.edu/resource/t8fZz9Y_pGw/" typeof="CategoryCode http://bibfra.me/vocab/lite/Concept"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.law.upenn.edu/resource/t8fZz9Y_pGw/">Pharmaceutical policy -- United States</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.law.upenn.edu/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.law.upenn.edu/">Biddle Law Library - University of Pennsylvania Law School</a></span></span></span></span></div>
